medigraphic.com

2020, Number 2

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2020; 21 (2)

Foot ulcer recurrence in diabetic patients who received heberprot-p® treatment

Castañeira JE, Febles SRJ

Language: Spanish
References: 20
Page: 1-11
PDF size: 302.11 Kb.


ABSTRACT

Introduction: Heberprot-P® is a novel medicine, unique among its kind, prescribed for diabetic foot ulcer therapy.
Objective: To evaluate frequency and characteristics of foot ulcer recurrence among diabetic patients treated with Heberprot-P®.
Methods: A descriptive-retrospective research was carried out. The study population consisted of 16 patients with diabetic foot ulcer recurrence from among the 841 treated with Heberprot-P® in polyclinics and hospitals in Matanzas Province from January to December 2018. The variables reviewed were taken to a database, and the results obtained were represented in charts and expressed in absolute and relative frequencies. The ethical considerations required for this study were respected.
Results: The age group 61-75 years and type 2 diabetic patients were the most affected. There were no differences between both sexes. Neuropathic diabetic foot with Wagner 2 severity appeared more frequently. Likewise, after the first injury and recurrence, a large number of patients with the disease were observed at 13-16 weeks, 56.2% of whom, were administered, during the first injury, 6-12 doses of Heberprot-P®. The total closure of the lesion was the most found outcome in the study population, and 1.9% of the treated patients presented recurrence of this.
Conclusions: The frequency and characteristics of foot ulcer recurrence in diabetic patients treated with Heberprot-P® were exposed.


REFERENCES

  1. Han Cho N, Kirigias J, Mbanya JC, Ogurstova K, Guariguata L, Rathmann W, et al. Diabetes Atlas de la FID. 8 Ed. Bruselas; 2017 [acceso 01/02/2017]. Disponible en: www.diabetesatlas.org

  2. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Estadísticas de salud en Cuba. Anuario estadístico 2016. La Habana: Ministerio de Salud Pública; 2017 [acceso 01/04/2017]. Disponible en: https://bvscuba.sld.cu/anuario-estadistico-de-cuba/

  3. Armstrong DG, Andrew JM, Boulton MD, Buss SA. Diabetic foot ulcers and their recurrence. Engl J Med. 2017;376:2367-75. DOI: https://doi.org/10.1056/NEJMra1615439

  4. Diabetes atlas. 7 Ed. Bruselas: International Diabetes Federation; 2015 [acceso 01/02/2017]. Disponible en: https:// www.diabetesatlas.org

  5. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005 Jan 12;293(2):217-28. DOI: https://doi.org/10.1001/jama.293.2.217

  6. Ulbrecht JS, Hurley T, Mauger DT, Cavanagh PR. Prevention of recurrent foot ulcers with plantar pressure-based in-shoe orthoses: The careful prevention multicenter randomized controlled trial. Diabetes Care. 2014 [acceso 01/02/2017];37:1982-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24760263

  7. Dubský M, Jirkovská A, Bem R, Fejfarová V, Skibová J, Schaper NC, et al. Risk factors for recurrence of diabetic foot ulcers: prospective follow-up analysis in the Eurodiale subgroup. Int Wound J. 2013 [acceso 01/02/2017];10:555-61. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22712631

  8. Bus SA, Waaijman R, Arts M, de Haart M, Busch-Westbroek T, Baal J, et al. Effect of custom-made footwear on foot ulcer recurrence in diabetes: a multicenter randomized controlled trial. Diabetes Care. 2013 Dec;36(12):4109-16. DOI: https://doi.org/10.2337/dc13-0996

  9. Berlanga J, Fernández JI, López E, López PA, del Río A, Valenzuela C, et al. Heberprot-P: un nuevo producto para el tratamiento de las úlceras complejas del pie diabético. MEDICC Rev. 2013 [acceso 04/02/2018];15(1). Disponible en: https://medicc.org/mediccreview/pdf.php?lang=&id=287.esp

  10. World Medical Association (WMA). Declaration of Helsinki. Ethical principles for medical research involving human subjects. 64th WMA General Assembly. Fortaleza, Brasil, 2013 Oct. JAMA. 2013 Oct;19:1-4. DOI: https://doi.org/10.1001/jama.2013.281053

  11. Yera Alos IB, Alonso-Carbonell L, Valenzuela-Silva CM, Tuero-Iglesias AD, Moreira Martínez M, Marrero-Rodríguez I, et al. Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. BMC Pharmacol Toxicol. 2013 [acceso 01/04/2017];14:44. Disponible en: https://doi.org/10.1186//2050-6511-14-44

  12. Kahraman M, Misir A, Kizkapan TB, Ozcamdalli M, Uzun E, Mutlu M. The long-term outcomes following the application of intralesional epidermal growth factor in patients with diabetic foot ulcers. J Foot Ankle Surg. 2019 Mar [acceso 01/04/2019];58(2):282-7. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30612874

  13. Moncayo Muñoz AP, Novillo Sarmiento CF. Frecuencia de pie diabético y manejo antibiótico en pacientes ingresados al hospital José Carrasco Arteaga, período 2010- 2015 [Tesis]. Cuenca, Ecuador; 2017 [acceso 01/04/2017]. Disponible en: http://dspace.ucuenca.edu.ec/bitstream/123456789/27909/1/Proyecto%20de%20Investigacion.pdf

  14. Waaijman R, de Haart M, Arts LMJ, Wever D, Verlouw AJWE, Nollet F, et al. Risk factors for plantar foot ulcer recurrence in neuropathic diabetic patients. Diabetes Care. 2014;37:1697-1705. DOI: https://doi.org/10.2337/dc13-2470

  15. Jiménez S, Rubio JA, Álvarez J, Lázaro-Martínez JL. Análisis de las re-ulceraciones en una unidad multidisciplinar de pie diabético tras la implementación de un programa de cuidado integrado del pie. Endocrinol Diabetes Nutr. 2018;65(8):438.e1-438.e10. DOI: https://doi.org/10.1016/j.endien.2018.03.017

  16. Dueñas Ramírez, HG. Factores de riesgo de recurrencia del pie diabético en el Hospital Regional Honorio Delgado, Arequipa, 2010- 2015. Repositorio.unsa.edu.pe.2016. 2016 [acceso 01/04/2017]. Disponible en: https://repositorio.unsa.edu.pe/handle/UNSA/3456

  17. Bus SA. Priorities in of floading the diabetic foot. Diabetes Metab Res Ver. 2012;28(Suppl 1):54-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22271724

  18. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351:48-55. DOI: https://doi.org/10.1056/NEJMcp032966

  19. Pafili K, Papanas N, Ziegler D. Neuropathy in diabetes: “One cannot begin It too soon”. Angiology. 2018 Oct;69(9):752-4. DOI: https://doi.org/10.1177/0003319717751759

  20. Feldman EL, Bennett DHL, Nave K-L, Jensen, TS. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017 Mar 22;93(6):1296-1313. DOI: https://doi.org/10.1016/j.neuron.2017.02.005




2020     |     www.medigraphic.com